We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alkido Pharma Inc | NASDAQ:AIKI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.56 | 3.53 | 3.98 | 0 | 01:00:00 |
Issuer:
|
|
Spherix Incorporated (NASDAQ: SPEX)
|
Securities Offered:
|
|
10,000,000 Series J Convertible Preferred Stock
|
Conversion
|
Each holder of Series J Preferred Stock may, from time to time,
convert any or all of such holder’s shares of Series J Preferred Stock into fully paid and non-assessable shares of Common Stock in an amount equal to one (1) share of the Corporation’s Common Stock for each one (1) share of Series J Preferred Stock surrendered, subject to the limitations set forth in the Description of Series J Preferred Stock.
|
|
Max Conversion Blocker
|
At no time may all or a portion of shares of Series J Preferred Stock
be converted if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning more than 9.99% of all of the Common Stock outstanding at such time. By written notice to the Corporation, a holder of Series J Preferred Stock may from time to time decrease the 9.99% Beneficial Ownership Limitation to any other percentage specified in such notice. Notwithstanding the foregoing, certain investors elected to have their beneficial ownership limitation be 4.99%.
|
|
Maximum Number of Securities Offered:
|
|
10,000,000
|
Price per Share:
|
|
$2.00
|
Estimated Net Proceeds:
|
|
$18.3 million, following payment by us of the placement agent fee and other offering expenses payable by us.
|
Dilution:
|
|
Dilution per share to investors participating in this offering will equal $1.94 based on our net tangible book value (deficit) as of March 31, 2014 after giving effect to the sale of 10,000,00 securities in this offering at a public offering price of $2.00 per preferred share, and after deducting placement agents’ fees and estimated offering expenses payable by us. The calculation of dilution per share to investors participating in this offering assumes:
• no exercise of outstanding options to purchase our common stock or outstanding warrants to purchase shares of our common stock;
• no issuances of our common stock upon the vesting of outstanding restricted stock units; and
• no exercise of outstanding warrants.
|
Lock-Up Provisions:
|
|
We, along with our executive officers, directors and certain of our security holders, have agreed to certain lock-up provisions with regard to future sales of our common stock and other securities convertible into or exercisable or exchangeable for common stock for a period of sixty (60) days after the offering as set forth in the placement agent agreement with Laidlaw and Company (UK) Ltd., who is acting as the placement agent in connection with the offering.
|
Use of Proceeds
|
Net proceeds will be used to meet our working capital needs and
general corporate purposes, including any payments that may be required under our Series I Preferred Stock held by Rockstar Consortium.
|
1 Year Alkido Pharma Chart |
1 Month Alkido Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions